Elevated Plasma <i>α</i>-Defensins (HNP1–3) Levels Correlated with IgA1 Glycosylation and Susceptibility to IgA Nephropathy

<div>Plasma <i>α</i>-defensins (HNP1–3) levels of IgAN patients and healthy controls. The line was mean levels of <i>α</i>-defensins for 169 IgAN patients (78.42 ng/mL) defined as the cut-off for dividing patients into two groups with high (above 78.42 ng/mL) and low (below 78.42 ng/mL) <i>α</i>-defensins levels.</div>

Disease Markers

fig1

Figure 1

Figure 1: Elevated Plasma <i>α</i>-Defensins (HNP1–3) Levels Correlated with IgA1 Glycosylation and Susceptibility to IgA Nephropathy 

Disease Markers

Elevated Plasma α-Defensins (HNP1–3) Levels Correlated with IgA1 Glycosylation and Susceptibility to IgA Nephropathy

Figure 1